Synthesis of current evidence from RCTs, data registries, and prospective studies involving the use of anti-TNFα agents for the treatment of inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis suggests an increased risk of serious infections and malignancies. Here, TNF is linked to psoriatic arthritis.